News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stentys Revenues for the First Half of 2012 Increase 92% over Prior Year


7/25/2012 9:51:28 AM

PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS (NYSE Euronext, FR0010949404 – STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), today reports its unaudited revenues for the half year ending 30 June 2012.

Read at BioSpace.com

comments powered by Disqus
Stentys
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES